Cytosorbents (CTSO) AI Stock Analysis

• Market Cap: $53.35M
• Dividend Yield: N/A
• Average Volume (3M): 76.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: -7.81%
• EPS Growth: 65.39%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.03
• Shares Outstanding: 62,761,806
• 10 Day Avg. Volume: 63,287
• 30 Day Avg. Volume: 76,802
• PEG Ratio: 0.06
• Price to Book (P/B): 4.46
• Price to Sales (P/S): 1.39
• P/FCF Ratio: -3.37
• Enterprise Value/Market Cap: 1.93
• Enterprise Value/Revenue: 3.08
• Enterprise Value/Gross Profit: 4.24
• Enterprise Value/Ebitda: -6.25
• 1Y Price Target: $1.00
• Price Target Upside: 17.65% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 43 Neutral
• Price Target: $1.00 ▲(17.65% Upside)

Cytosorbents' overall stock score is primarily impacted by its challenging financial performance, characterized by high leverage and negative cash flows. The technical analysis indicates a bearish trend, and poor valuation metrics further weigh down the score. While the earnings call highlighted some positive developments, regulatory challenges and financial pressures remain significant concerns.

Positive Factors

Product Sales Growth

The 9% YoY increase in product sales highlights the company's ability to grow its market presence and demand for its products, indicating a positive trend in revenue generation.

Operational Efficiency

A strong gross margin of 71% suggests effective cost management at the production level, which can support long-term profitability as the company scales.

German Market Success

The success in the German market reflects strategic realignment and potential for further international expansion, enhancing the company's competitive position.

Negative Factors

Regulatory Challenges

Regulatory setbacks for DrugSorb ATR can delay market entry and revenue potential in North America, impacting growth prospects and strategic plans.

High Leverage

High leverage poses a risk to financial stability, limiting the company's ability to invest in growth opportunities and increasing vulnerability to economic downturns.

Negative Cash Flows

Negative cash flows indicate liquidity challenges, hindering the company's ability to sustain operations and invest in future growth without external financing.

Cytosorbents Business Overview & Revenue Model

Company Description

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Cytosorbents generates revenue primarily through the sale of its CytoSorb devices and related products to hospitals and healthcare providers. The company employs a direct sales model in certain markets, while also working with distributors and partners to expand its reach. Key revenue streams include the sale of disposable CytoSorb cartridges, which are used in conjunction with the device for blood purification during critical care treatments. The company has established significant partnerships with medical institutions and research organizations, which not only enhance its product visibility but also facilitate clinical studies that can lead to broader adoption of its technologies. Additionally, Cytosorbents may explore opportunities for reimbursement from healthcare payers, further contributing to its earnings potential.

Cytosorbents Financial Statement Overview

Summary

Cytosorbents faces significant financial challenges with negative net profit and EBIT margins, high leverage, and negative cash flows. Despite strong gross profit margins, the company's high debt levels and liquidity issues pose risks to financial stability.

Income Statement

Cytosorbents has shown a slight improvement in revenue growth with a TTM growth rate of 2.37%. However, the company continues to face significant profitability challenges, as indicated by negative net profit and EBIT margins. The gross profit margin remains strong at 72.57%, suggesting efficient cost management at the production level, but overall profitability is hindered by high operating expenses.

Balance Sheet

The company's balance sheet reflects high leverage with a debt-to-equity ratio of 2.34, indicating a reliance on debt financing. The return on equity is negative, highlighting ongoing losses. The equity ratio stands at 24.14%, suggesting a moderate level of equity financing relative to total assets, but the high debt levels pose a risk to financial stability.

Cash Flow

Cytosorbents is experiencing negative operating and free cash flows, with a declining free cash flow growth rate of -24.67% in the TTM period. The operating cash flow to net income ratio is close to 1, indicating that cash flow generation is in line with net losses, but the overall cash flow situation remains weak, posing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.48M	35.59M	31.08M	29.36M	40.11M	39.45M
Gross Profit	24.30M	25.13M	21.95M	15.40M	29.06M	28.40M
EBITDA	-16.49M	-19.26M	-27.88M	-32.77M	-21.62M	-9.71M
Net Income	-9.75M	-20.72M	-29.25M	-32.81M	-24.56M	-7.84M
Balance Sheet
Total Assets	47.99M	47.37M	52.96M	63.23M	89.52M	89.95M
Cash, Cash Equivalents and Short-Term Investments	10.20M	3.28M	14.13M	22.14M	52.14M	71.42M
Total Debt	27.06M	26.89M	18.31M	18.25M	13.82M	1.03M
Total Liabilities	36.40M	36.26M	29.48M	27.86M	26.94M	10.73M
Stockholders Equity	11.59M	11.11M	23.48M	35.38M	62.58M	79.22M
Cash Flow
Free Cash Flow	-10.29M	-14.71M	-22.59M	-34.69M	-18.29M	-7.29M
Operating Cash Flow	-9.78M	-14.43M	-21.66M	-28.23M	-14.01M	-5.61M
Investing Cash Flow	-601.55K	-669.43K	-936.24K	-6.46M	-4.28M	-1.68M
Financing Cash Flow	6.90M	9.33M	14.47M	4.96M	715.20K	66.35M

Cytosorbents Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTSO, the sentiment is Negative. The current price of 0.85 is below the 20-day moving average (MA) of 0.91, below the 50-day MA of 0.94, and below the 200-day MA of 1.01, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 35.70 is Neutral, neither overbought nor oversold. The STOCH value of 17.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTSO.

Cytosorbents Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	64 Neutral	$97.17M	12.60	4.92%	―	1.43%	-20.12%
SRTS	61 Neutral	$54.09M	―	-1.62%	―	3.30%	-112.70%
XTNT	57 Neutral	$109.48M	-21.57	-9.80%	―	15.16%	-39.18%
HYPR	53 Neutral	$102.16M	―	-77.26%	―	-9.59%	8.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NSPR	45 Neutral	$93.45M	-2.70	-123.51%	―	7.60%	-0.78%
CTSO	43 Neutral	$53.35M	-4.62	-68.84%	―	-7.81%	65.39%

Cytosorbents Corporate Events

Cytosorbents Faces Nasdaq Non-Compliance Notice

On October 2, 2025, CytoSorbents Corporation received a notice from Nasdaq for non-compliance with the Minimum Bid Price Requirement, as its stock price remained below $1.00 for 30 consecutive business days. The company has until March 31, 2026, to regain compliance by ensuring its stock price meets or exceeds $1.00 for at least 10 consecutive days. Failure to comply could lead to an additional compliance period if an acceptable plan is presented to Nasdaq. The company is actively monitoring its stock price and exploring options to meet the requirement.

The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.

Cytosorbents Corp Q2 2025 Earnings Call Highlights

Cytosorbents Corp’s recent earnings call reflected a balanced sentiment, highlighting positive growth in product sales and strategic advancements in the German market, while also addressing significant regulatory hurdles with the DrugSorb ATR product. Despite an increase in operational costs, the company remains optimistic about its appeal processes and potential future growth.

CytoSorbents Reports Positive Q2 2025 Financial Results

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through its innovative blood purification technologies. The company specializes in removing toxic substances from blood, offering solutions for critical illnesses such as sepsis and septic shock.